In our cohort of patients with breast cancer ≤ 31 years, P/LP variants were found in 13% of cases, the majority of which were identified in BRCA1, BRCA2, and TP53 (6.8%, 3.4%, and 2.3%, respectively). Here, TP53 is linked to breast cancer.